FDA approves Octapharma USA’s IND application to begin trial with severe Covid-19 patients

This article was originally published here

Octagam 10% is an immune globulin intravenous (human) liquid preparation designated to treat chronic immune thrombocytopenic purpura (ITP) in adults. According to the company, the primary objective of

The post FDA approves Octapharma USA’s IND application to begin trial with severe Covid-19 patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply